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Abstract
Introduction Recent data about radiographic progression
during treatment with tumor necrosis factor-alpha (TNF-α)
blocker agents in patients with ankylosing spondylitis (AS) have
prompted an intensive discussion about the link between
inflammation/bone destruction and new bone formation and the
order of events. Therefore, we analysed parameters of cartilage
degradation, neoangiogenesis, and new bone formation in
different cohorts of patients with axial spondyloarthritis with and
without treatment with TNF-α blocker agents.
Method TNF-α blocker-naïve AS patients were investigated for
serum levels of metalloproteinase-3 (MMP-3) (n = 71),
vasoendothelial growth factor (VEGF) (n = 50), and bone-
specific alkaline phosphatase (BALP) (n = 71) at baseline and
after 1 and 2 years. This was compared with 34 adalimumab-
treated patients with axial spondyloarthritis (22 AS and 12 non-
radiographic axial spondyloarthritis patients) before and after 36
to 52 weeks of treatment.
Results There were no significant changes in serum levels of
MMP-3 (P > 0.05), VEGF (P > 0.05), and BALP (P > 0.05) in a
large cohort of TNF-α blocker-naïve AS patients followed for 2
years. In contrast, adalimumab-treated spondyloarthritis (AS and
non-radiographic axial spondyloarthritis) patients had a
significant decrease of VEGF (P < 0.001) and MMP-3 (P =
0.022) after 36 to 52 weeks of therapy. Most interestingly, the
level of BALP increased significantly after 36 to 52 weeks of
therapy (P  < 0.001). A decrease in MMP-3 serum levels
correlated significantly to an increase of BALP (r = -0.398, P =
0.02). In the case of VEGF, there was a negative correlation
without significance (r = -0.214, P > 0.05).
Conclusions Rising levels of BALP and the negative correlation
between MMP-3 and BALP in spondyloarthritis patients with
TNF-α blocker treatment indicate that new bone formation in AS
occurs if inflammation is successfully treated and might be part
of a healing process.
Introduction
Ankylosing spondylitis (AS) is a chronic inflammatory disease
with inflammation in the spine which can lead to bone ero-
sions, new bone formation, and ankylosis in the spine. Inflam-
mation is partly mediated by tumor necrosis factor-alpha (TNF-
α) [1]. Treatment of patients with active AS with the currently
approved TNF-blocking agents infliximab [2], etanercept [3],
and adalimumab [4] has been shown to be highly effective for
the improvement of signs, symptoms, and function and the
reduction of both C-reactive protein (CRP) and active inflam-
mation in the sacroiliac joints and the spine as shown by mag-
netic resonance imaging [5]. Histopathological studies from
intervertebral discs [6], femoral heads [7,8], sacroiliac joint
[1,9], manubriosternal junction [10], and facet joints [11,12]
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suggest that a subchondral inflammation at the interface
between bone and cartilage – a subchondral osteitis – could
be the primary site of the AS immunopathology. In recent his-
topathological studies, we have reported mononuclear cell
aggregates, cartilage degradation, high microvessel density,
and increased osteoclastic activity at sites of acute inflamma-
tion [8]. In areas of less or no inflammation, repair mechanisms
such as increased osteoblast activity were seen [8]. The anal-
ysis of serum biomarkers reflecting inflammation, bone
destruction, and new bone formation could be helpful for a
better understanding of the sequence of events in the spine.
Therefore, we analysed vasoendothelial growth factor (VEGF),
metalloproteinase-3 (MMP-3), and bone-specific alkaline
phosphatase (BALP) in the sera of different cohorts of patients
with axial spondyloarthritis (SpA). VEGF is a potent ang-
iogenic vasoactive molecule that increases vascular permea-
bility and is a specific mitogen for endothelial cells [13]. It has
been suggested that it correlates well with inflammation and
disease activity in spondyloarthritides [14]. MMP-3 degrades
extracellular matrix proteins and is involved in disruptive events
in the cartilage and bone of inflamed joints [15]. Recent publi-
cations suggest that it is closely related to inflammation and
high disease activity in AS [16-18] and that it also correlates
significantly to radiographic progression [19]. BALP was cho-
sen as an indicator for new bone formation because skeletal
growth and bone consolidation correlate well with serum lev-
els of bone biochemical markers like BALP and osteocalcin
[20].
Materials and methods
Tumor necrosis factor-alpha blocker-naïve patients
In the era before TNF-α-blocking treatment, we had collected
sera from AS patients at baseline and after 1 and 2 years. All
71 AS patients who were included in this study belong to the
German Spondyloarthritis Inception Cohort (GESPIC) and
were selected because sera at baseline, after 1 year, and after
2 years were available. The mean age of this cohort was 37.75
± 10.67 years, the mean disease duration was 5.28 ± 2.66
years, 61.97% of the patients were male, and 81.69% were
HLA-B27-positive. The Bath Ankylosing Spondylitis Disease
Activity Index (BASDAI), erythrocyte sedimentation rate (ESR),
and CRP were taken at all time points. Serum levels of BALP,
VEGF (n = 50), and MMP-3 were measured at the given time
points. All patients gave informed consent for this study. Per-
mission for this study was given by the local ethics committee
of the Charité Berlin, Campus Benjamin Franklin. The majority
of patients used non-steroidal anti-inflammatory drugs, and
none of them was on disease-modifying anti-rheumatic drugs
or steroids.
Adalimumab-treated patients
All 34 patients treated with adalimumab were diagnosed as
axial SpA [21]. Twenty-two patients with the diagnosis of AS
according to the modified New York criteria (mean age: 44.73
± 12.09 years, mean disease duration: 15.33 ± 10.15 years)
and 12 patients with non-radiographic axial SpA [22] diag-
nosed by magnetic resonance imaging and typical clinical
symptoms (mean age: 31.67 ± 6.80 years, mean disease
duration: 3.58 ± 2.91 years) were included in this analysis.
These patients either were part of other studies that have been
reported elsewhere [22,23] or were treated open-label. Sera
from AS patients were obtained during another clinical trial
[23] or during open-label therapy. The mean age of all patients
treated with adalimumab was 40.12 ± 12.2 years, and the
mean disease duration was 10.63 ± 9.9 years. Serum was
taken before and 12 and 36 to 52 weeks after treatment with
adalimumab was initiated. Each patient received 40 mg of
adalimumab subcutaneously every other week. The majority of
patients used non-steroidal anti-inflammatory drugs, and none
of them was on disease-modifying anti-rheumatic drugs or
steroids. All patients gave informed consent for this study.
Serum enzyme-linked immunosorbent assay of VEGF, 
MMP-3, and BALP
Serum levels of VEGF, MMP-3, and BALP were measured by
commercially available enzyme-linked immunosorbent assay
(ELISA) kits: Quantikine® Human MMP-3 (total) Immunoassay
(R&D Systems, Wiesbaden-Nordenstadt, Germany) for MMP-
3, Quantikine® Human VEGF Immunoassay (R&D Systems)
for VEGF, and MetraBAP (Quidel, San Diego, USA) for
BALP). Analysis was performed in accordance with the
instructions of the manufacturers. For reasons of availability,
21 of the 71 TNF-α-naïve AS patients were excluded from
VEGF analysis.
Statistical analysis
Serum levels of MMP-3, VEGF, and BALP between baseline
and different time points were analysed using the Wilcoxon
test. The correlation of differences in the serum levels of MMP-
3, VEGF, BALP, and CRP before and after treatment with
adalimumab was also analysed by using the Spearman rank
correlation coefficient. The non-parametric Brunner test was
applied to compare changes in serum levels of VEGF, MMP-
3, or BALP between AS and non-radiographic axial SpA
patients by taking the baseline status of VEGF, MMP-3, or
BALP into account.
Results
Correlation of clinical parameters with serum levels of 
VEGF, MMP-3, and BALP in patients with 
spondyloarthritis
We correlated the serum levels of VEGF, MMP-3, and BALP
to clinical parameters in the cohort of TNF-α blocker-naïve AS
patients. VEGF correlated well to CRP (r = 0.307, P = 0.030),
ESR (n = 49) (r = 0.370, P = 0.009), and BASDAI (r = 0.340,
P = 0.018) at baseline and after 2 years (CRP: r = 0.361, P =
0.010; ESR: r = 0.372, P = 0.011; BASDAI: r = 0.496, P =
0.003). MMP-3 correlated well to CRP at baseline (r = 0.291,
P = 0.014) but not to CRP after 2 years (r = 0.112, P > 0.05).
MMP-3 did not correlate to ESR at baseline or after 2 years (rAvailable online http://arthritis-research.com/content/10/5/R125
Page 3 of 8
(page number not for citation purposes)
= 0.011, P > 0.05 and r = -0.139, P > 0.05) or to BASDAI (r
= -0.039, P > 0.05 and r = -0.062, P > 0.05). BALP correlated
to CRP at baseline (r = 0.333, P = 0.005) but not after 2 years
(r = 0.012, P > 0.05). We did not find a correlation of BALP
to ESR (r = 0.176, P > 0.05 and r = -0.082, P > 0.05) or BAS-
DAI (r = 0.069, P > 0.05 and r = -0.222, P > 0.05) at baseline
or after 2 years.
No changes in serum levels of VEGF, MMP-3, and BALP 
in a tumor necrosis factor-alpha blocker-naïve cohort 
over a 2-year observation period
The serum level of VEGF was 325.34 ± 176.09 pg/mL at
baseline and did not change significantly if compared with
serum levels after 1 year (358.08 ± 205.06 pg/mL, P > 0.05)
and 2 years (339.14 ± 198.03 pg/mL, P < 0.05) (Figure 1).
Similarly, serum levels of MMP-3 remained stable and were
19.23 ± 14.81 ng/mL at baseline and 19.03 ± 15.12 ng/mL
(P > 0.05) after 1 year and 19.96 ± 17.70 ng/mL after 2 years
(P > 0.05) (Figure 1). Also, the serum level of BALP did not
show any significant change over the course of 2 years: 14.37
± 4.08 U/L after baseline, 14.18 ± 4.56 U/L after 1 year (P >
0.05), and 14.75 ± 4.45 U/L after 2 years (P > 0.05) (Figure
1) on the group level.
Serum levels of VEGF, MMP-3, and BALP during tumor 
necrosis factor-alpha blocker treatment with 
adalimumab
The majority of patients with axial SpA reported a major benefit
from TNF-α therapy with adalimumab. The mean BASDAI
decreased by more than 3 points after 36 to 52 weeks (P <
0.001). ESR (P  = 0.007) and CRP (P  < 0.001) also
decreased significantly. Accordingly, a decrease of VEGF and
MMP-3 serum levels was observed: serum levels of VEGF
were 324.6 ± 179.8 pg/mL before therapy and decreased sig-
nificantly to 277.1 ± 155.37 pg/mL after 12 weeks and to
250.7 ± 120.8 pg/mL after 36 to 52 weeks of therapy (P <
0.001). Serum levels of MMP-3 were 28.0 ± 28.5 ng/mL
before therapy and decreased significantly to 23.5 ± 27.1 ng/
Figure 1
Mean serum levels of vasoendothelial growth factor (VEGF), metalloproteinase-3 (MMP-3), and bone-specific alkaline phosphatase (BALP) at base- line and after 1 and 2 years in a tumor necrosis factor-alpha blocker-naïve cohort of ankylosing spondylitis patients Mean serum levels of vasoendothelial growth factor (VEGF), metalloproteinase-3 (MMP-3), and bone-specific alkaline phosphatase (BALP) at base-
line and after 1 and 2 years in a tumor necrosis factor-alpha blocker-naïve cohort of ankylosing spondylitis patients. ns, not significant.Arthritis Research & Therapy    Vol 10 No 5    Appel et al.
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mL after 12 weeks and to 19.02 ± 15.83 ng/mL after 36 to 52
weeks of therapy (P = 0.022). In contrast, the serum level of
BALP increased significantly during therapy: from 21.6 ± 8.1
U/L before therapy to 23.2 ± 8.8 U/L after 12 weeks and to
25.4 ± 11.6 U/L after 36 to 52 weeks of therapy (P < 0.001)
(Figure 2).
Differences in serum levels of VEGF, MMP-3, and BALP 
in response to adalimumab in ankylosing spondylitis 
and non-radiographic axial spondyloarthritis
We also addressed the question of whether serum levels of
VEGF, MMP-3, and BALP differed significantly between
patients with non-radiographic axial SpA (n = 12) and AS (n =
22) diagnosed by the modified New York criteria. Serum levels
of VEGF decreased significantly in patients with AS (308.90
± 175.74 pg/ml at baseline and 224.10 ± 108.90 pg/ml after
36 to 52 weeks, P = 0.004) and non-significantly in patients
with early axial SpA (353.40 ± 191.26 pg/ml at baseline and
299.56 ± 130.87 pg/ml after 36 to 52 weeks, P = 0.084).
Serum levels of MMP-3 also decreased significantly in AS
(30.12 ± 32.16 ng/ml at baseline and 20.31 ± 18.77 ng/ml
after 36 to 52 weeks, P = 0.022) and non-significantly in early
axial SpA (24.20 ± 21.07 ng/ml at baseline and 16.63 ± 8.34
ng/ml after 36 to 52 weeks of therapy, P = 0.388). Interest-
ingly, serum levels of BALP increased significantly in AS
(21.43 ± 9.21 U/l at baseline and 26.50 ± 13.17 U/l after 36
to 52 weeks of therapy, P = 0.001) but less clearly and non-
significantly in non-radiographic axial SpA (22.01 ± 5.90 U/l at
baseline and 23.46 ± 7.96 U/l after 36 to 52 weeks of therapy,
P = 0.308). Comparisons of the change in scores between AS
and non-radiographic axial SpA adjusted for the baseline sta-
tus revealed no significant differences (VEGF: P  = 0.294,
MMP-3: P = 0.324, BALP: P = 0.128).
Correlation between differences in serum levels of 
VEGF, MMP-3, BALP, and C-reactive protein before and 
after 36 to 52 weeks of treatment with adalimumab
Next, we correlated the differences of biomarker serum levels
at baseline and after 36 to 52 weeks of treatment with adali-
mumab (Figure 3). Interestingly, the difference of serum levels
of VEGF between weeks 36 to 52 and baseline (d_VEGF) and
d_MMP-3 correlated nicely with d_CRP (VEGF: r = 0.498, P
Figure 2
Mean serum levels of vasoendothelial growth factor (VEGF), metalloproteinase-3 (MMP-3), and bone-specific alkaline phosphatase (BALP) in  patients with axial spondyloarthritis before and after 12 and 36 to 52 weeks of treatment with adalimumab Mean serum levels of vasoendothelial growth factor (VEGF), metalloproteinase-3 (MMP-3), and bone-specific alkaline phosphatase (BALP) in 
patients with axial spondyloarthritis before and after 12 and 36 to 52 weeks of treatment with adalimumab. *P < 0.05. ns, not significant.A va ila b le  o n lin e http://arthritis-research.com/content/10/5/R125
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= 0.004; MMP-3: r = 0.454, P = 0.009) and we observed a
non-significant tendency of negative correlation between
d_BALP and d_CRP (r = -0.322, P = 0.073). Most interest-
ingly, if d_BALP and d_MMP-3 were analysed, a statistically
significant negative correlation was found (r = -0.398, P =
0.02). A correlation analysis of d_BALP and d_VEGF also
revealed a tendency of negative correlation (r = -0.214, P >
0.05). Such correlations of differences in d_BALP and
d_MMP-3 over time were not observed in the sera of AS
patients from the TNF-α blocker-naïve cohort.
Discussion
In this study, we measured the serum levels of VEGF, MMP-3,
and BALP in a cohort of TNF-α blocker-naïve AS patients dur-
ing an observation period of 2 years and compared these
results with a cohort of adalimumab-treated AS patients. If we
correlated serum biomarkers to clinical parameters in TNF-α
blocker-naïve AS patients, we observed a good correlation of
VEGF with CRP, ESR, and BASDAI. This is in line with previ-
ous reports showing that VEGF is a good indicator of high dis-
ease activity in patients with AS [14,24,25]. VEGF serum
levels were higher in AS patients than in healthy controls and
showed a significant correlation with BASDAI, ESR, and CRP
in a previous study [24]. We could also observe a correlation
of MMP-3 with CRP at baseline. However, the correlation of
MMP-3 with ESR and BASDAI was not significant. Similar
results were reported recently by Woo and colleagues [26].
Nonetheless, other studies revealed significant correlations of
serum levels of MMP-3 with CRP, ESR, and BASDAI (respec-
tively) [17] or with ESR and BASDAI but not with CRP [27].
We obtained no clear correlation of serum levels of BALP with
parameters of disease activity. Besides a correlation of BALP
Figure 3
Correlation of differences in serum levels at baseline and 1 year of (a) metalloproteinase-3 (d_MMP-3) and C-reactive protein (d_CRP), (b) vasoen- dothelial growth factor (d_VEGF) and d_CRP, (c) bone-specific alkaline phosphatase (d_BALP) and d_CRP, and (d) d_MMP-3 and d_BALP Correlation of differences in serum levels at baseline and 1 year of (a) metalloproteinase-3 (d_MMP-3) and C-reactive protein (d_CRP), (b) vasoen-
dothelial growth factor (d_VEGF) and d_CRP, (c) bone-specific alkaline phosphatase (d_BALP) and d_CRP, and (d) d_MMP-3 and d_BALP.Arthritis Research & Therapy    Vol 10 No 5    Appel et al.
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with CRP at baseline, all other analysis revealed no significant
correlations. Such a correlation of BALP with CRP was also
observed in a study of 56 AS patients [28] but not in a recent
analysis of 26 AS patients [26]. Thus, current data, including
our present study, give evidence that serum levels of VEGF are
a good parameter to indicate disease activity in AS while there
are some contradictory results about the use of MMP-3 serum
levels to indicate disease activity. Finally, BALP seems not to
be a sensitive parameter to indicate higher disease activity in
AS.
We next addressed the question of whether serum levels of
these biomarkers change in the same patients during an
observation period of 2 years without treatment with a TNF-α
blocker. Interestingly, serum levels of all three biomarkers in
this cohort remained stable during this period without signifi-
cant changes in comparison with baseline, which is reported
for the first time in the case of MMP-3 serum levels. A longitu-
dinal study of VEGF and BALP serum levels during an obser-
vation period of 2 years was not reported before, but stable
serum levels of VEGF and BALP were also seen in a cohort of
78 AS patients over the course of 24 weeks [24,25]. How-
ever, in the cohort of SpA patients with the TNF blocker adal-
imumab, we observed a significant decrease of MMP-3 after
36 to 52 weeks. The difference of serum levels of MMP-3 after
36 to 52 weeks compared with baseline correlated signifi-
cantly to the decrease of CRP. A decrease of MMP-3 levels
during treatment with TNF-α blocker treatment was also
reported recently in AS patients receiving infliximab or etaner-
cept [18,26,29].
Adalimumab-treated SpA patients also displayed a significant
decrease of VEGF after 36 to 52 weeks. The difference of
serum levels of VEGF after 36 to 52 weeks compared with
baseline correlated significantly to a decrease of CRP (differ-
ence from 36 to 52 weeks to baseline). The influence of TNF-
α blocker agents on serum levels of VEGF has been reported
only for infliximab-treated patients. In 201 infliximab-treated AS
patients, serum levels of VEGF decreased significantly during
treatment within an observation period of 24 weeks [24]. Our
data indeed support the view that a decrease of VEGF serum
levels is a good indicator of response in TNF-α blocker-treated
AS patients.
In our cohort of adalimumab-treated SpA patients, the serum
levels of BALP increased significantly during 36 to 52 weeks
of treatment. This is in line with recent reports of AS patients
treated with infliximab [25] and etanercept [26]: in 26 AS
patients treated with etanercept, BALP serum levels increased
significantly during an observation period of 12 weeks; this
correlated to osteocalcin serum levels, which is another
marker for increased osteoblast activity [26]. Seventy-eight inf-
liximab-treated AS patients showed a significant increase of
BALP serum levels after 102 weeks but not after 24 weeks of
observation [25]. Interestingly, the differences of serum levels
of BALP and MMP-3 between baseline and 36 to 52 weeks
displayed a significant negative correlation in our analysis. This
finding supports the idea that successful treatment of inflam-
mation is closely linked to the induction of new bone formation
[30]. MMP-3 was recently suggested as an independent pre-
dictor of new bone formation [19]. Such a high level of MMP-
3 at baseline is suggestive of structural damage that might
undergo repair if inflammation is successfully treated [30].
Other studies analysing biomarkers during treatment with
TNF-α-blocking agents also observed a switch from degrada-
tion to anabolic mechanisms. During treatment of AS patients
with etanercept, cartilage degradation illustrated by serum lev-
els of type II collagen fragment (C2C) decreased during treat-
ment whereas the serum level of procollagen type I N-terminal
propeptide (PINP), a marker for new bone formation,
increased significantly [31]. Increased serum levels of BALP
might reflect not only new bone formation in repair tissue of
inflammatory lesions in AS but also a more general increase of
bone mineral density in AS patients treated with TNF-α-block-
ing agents [32].
The modified New York criteria normally have to be fulfilled for
a diagnosis of AS. This implies the presence of sacroiliitis as
shown by x-rays [33]. Our cohort of axial SpA patients treated
with TNF-α blockers included patients with AS and non-radio-
graphic axial SpA [21,22]. Subdividing these two groups (AS
n = 22 and non-radiographic AS n = 12) and performing a
subanalysis revealed the interesting result that serum levels of
VEGF, MMP-3, and BALP did not differ significantly in the two
groups of patients. Moreover, serum levels of MMP-3 and
VEGF both decreased during therapy and BALP increased in
both groups of patients. However, this was significant in AS
patients only.
Conclusions
Biomarkers in the serum of patients have been increasingly
used to get a better idea about bone-destructive and bone-
anabolic phases in different forms of arthritides, including
spondyloarthritides. For the first time, here we report a nega-
tive correlation between bone-degrading parameters and
parameters of new bone formation during treatment with a
TNF blocker such as adalimumab in axial SpA.
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